Guggenheim lowered the firm’s price target on Ardent Health (ARDT) to $15 from $18 and keeps a Buy rating on the shares. Management will have to execute on core stability and ultimately more normalized growth considerations now that the DPP-related EBITDA pops are behind them, the analyst tells investors in a post-earnings note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health price target lowered to $14.50 from $17 at UBS
- Block upgraded, Dell downgraded: Wall Street’s top analyst calls
- Ardent Health downgraded to Sector Weight from Overweight at KeyBanc
- Cautious Outlook on Ardent Health Partners, Inc. Amidst Uncertainty in Financial Projections and Rising Costs
- Ardent Health Partners, Inc.: Buy Rating Affirmed Amid Low Valuation and Cost-Saving Potential